Literature DB >> 11724793

The lymphocyte metalloprotease MDC-L (ADAM 28) is a ligand for the integrin alpha4beta1.

Lance C Bridges1, Patricia H Tani, Krista R Hanson, Charles M Roberts, Matthew B Judkins, Ron D Bowditch.   

Abstract

The interaction of lymphocytes with other cells is critical for normal immune surveillance and response. MDC-L (ADAM 28), a member of the ADAM (a disintegrin and metalloprotease) protein family, is expressed on the surface of human lymphocytes. ADAMs possess a disintegrin-like domain similar in sequence to small non-enzymatic snake venom peptides that act as integrin antagonists. We report here that the disintegrin domain of MDC-L is recognized by the leukocyte integrin alpha(4)beta(1). Recombinant Fc fusion proteins possessing the disintegrin domain of MDC-L supported adhesion of the T-lymphoma cell line, Jurkat, in a concentration- and divalent cation-dependent manner. Adhesion of Jurkat cells to the disintegrin domain of MDC-L was inhibited by an anti-MDC-L monoclonal antibody (mAb), Dis1-1. The epitope for mAb Dis1-1 was localized within 59 residues of the disintegrin domain. Recombinant expression of this 59-residue fragment of the disintegrin domain also supported cell adhesion. Adhesion of Jurkat cells to the MDC-L disintegrin domain was specifically inhibited by anti-alpha(4) and anti-beta(1) function-blocking mAbs. Furthermore, adhesion of various cell lines to MDC-L correlated with expression of the integrin alpha(4)-subunit. Transfected K562 cells expressing alpha(4)beta(1) adhered to the disintegrin domain in contrast to non-transfected K562 cells. We further investigated the binding of recombinant MDC-L disintegrin domain (rDis-Fc) in solution. The rDis-Fc was found to bind to Jurkat cells in solution in a concentration-dependent and saturable manner. Both adhesion and solution binding of rDis-Fc was inhibited by the alpha(4)beta(1) ligand mimetic CS-1 peptide. Additionally, recognition of the MDC-L disintegrin domain required "activation" of lymphocyte beta(1) integrins. The interaction of MDC-L with alpha(4)beta(1) may potentially regulate metalloprotease function by targeting or sequestering the active protease on the cell surface. These results suggest a potential role for the lymphocyte ADAM, MDC-L, in the interaction of lymphocytes with alpha(4)beta(1)-expressing leukocytes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11724793     DOI: 10.1074/jbc.M109538200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Anti-adhesion molecule therapy for inflammatory bowel disease.

Authors:  Subrata Ghosh; Remo Panaccione
Journal:  Therap Adv Gastroenterol       Date:  2010-07       Impact factor: 4.409

2.  Cooperation of the metalloprotease, disintegrin, and cysteine-rich domains of ADAM12 during inhibition of myogenic differentiation.

Authors:  Haiqing Yi; Joanna Gruszczynska-Biegala; Denise Wood; Zhefeng Zhao; Anna Zolkiewska
Journal:  J Biol Chem       Date:  2005-04-23       Impact factor: 5.157

3.  Genome-wide association identifies diverse causes of common variable immunodeficiency.

Authors:  Jordan S Orange; Joseph T Glessner; Elena Resnick; Kathleen E Sullivan; Mary Lucas; Berne Ferry; Cecilia E Kim; Cuiping Hou; Fengxiang Wang; Rosetta Chiavacci; Subra Kugathasan; John W Sleasman; Robert Baldassano; Elena E Perez; Helen Chapel; Charlotte Cunningham-Rundles; Hakon Hakonarson
Journal:  J Allergy Clin Immunol       Date:  2011-04-17       Impact factor: 10.793

4.  Phenotypic analysis of Meltrin alpha (ADAM12)-deficient mice: involvement of Meltrin alpha in adipogenesis and myogenesis.

Authors:  Tomohiro Kurisaki; Aki Masuda; Katsuko Sudo; Junko Sakagami; Shigeki Higashiyama; Yoichi Matsuda; Akira Nagabukuro; Atsushi Tsuji; Yoichi Nabeshima; Masahide Asano; Yoichiro Iwakura; Atsuko Sehara-Fujisawa
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

Review 5.  Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment.

Authors:  E G Quetglas; A Armuzzi; S Wigge; G Fiorino; L Barnscheid; M Froelich; Silvio Danese
Journal:  Eur J Clin Pharmacol       Date:  2015-05-27       Impact factor: 2.953

6.  Multiple non-catalytic ADAMs are novel integrin α4 ligands.

Authors:  Lei Wang; Jason A Hoggard; Erica D Korleski; Gideon V Long; Brandy C Ree; Kenneth Hensley; Stephen R Bond; Tyra G Wolfsberg; JianMing Chen; Tonya N Zeczycki; Lance C Bridges
Journal:  Mol Cell Biochem       Date:  2017-09-14       Impact factor: 3.396

7.  ADAM28 is elevated in humans with the metabolic syndrome and is a novel sheddase of human tumour necrosis factor-α.

Authors:  Jeremy B M Jowett; Yasunori Okada; Peter J Leedman; Joanne E Curran; Matthew P Johnson; Eric K Moses; Harald H H Goring; Satsuki Mochizuki; John Blangero; Leah Stone; Holly Allen; Chris Mitchell; Vance B Matthews
Journal:  Immunol Cell Biol       Date:  2012-09-25       Impact factor: 5.126

8.  Gene Expression Profiling Reveals Regulation of ERK Phosphorylation by Androgen-Induced Tumor Suppressor U19/EAF2 in the Mouse Prostate.

Authors:  Fei Su; Bruna R S Correa; Jianhua Luo; Ricardo Z N Vencio; Laura E Pascal; Zhou Wang
Journal:  Cancer Microenviron       Date:  2013-02-26

Review 9.  ADAM 33 and its association with airway remodeling and hyperresponsiveness in asthma.

Authors:  Stephen T Holgate; Donna E Davies; Steuart Rorke; Julie Cakebread; Gillian Murphy; Robert M Powell; John W Holloway
Journal:  Clin Rev Allergy Immunol       Date:  2004-08       Impact factor: 8.667

10.  9-cis-retinoic acid promotes cell adhesion through integrin dependent and independent mechanisms across immune lineages.

Authors:  Jarrett T Whelan; Jianming Chen; Jabin Miller; Rebekah L Morrow; Joshuah D Lingo; Kaitlin Merrell; Saame Raza Shaikh; Lance C Bridges
Journal:  J Nutr Biochem       Date:  2012-08-25       Impact factor: 6.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.